Steven W. Pipe, MD, on Conducting Further Research in Hemophilia

Video

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed current studies evaluating gene therapies in hemophilia.

“What we're gearing up for this year is how to prepare the hemophilia treatment centers to roll out and maintain gene therapy programs with good safety and outcomes for patients in the commercial setting. So, we'll be getting sites ready and patients ready to embrace this technology, if it's right for them.”

Hemophilia A and B are growing indications for gene and cell therapy programs, with the goal of addressing Factor VIII deficiency in hemophilia A and Factor IX deficiency in hemophilia B.

CGTLive had the opportunity to speak with a veteran of the field, Steven W. Pipe, MD, director, Pediatric Hemophilia and Coagulation Disorders Program, CS Mott Children’s Hospital and professor, University of Michigan Health.

Pipe has been involved with multiple gene therapy investigations. Among his investigations are the pivotal GENEr8-1 (NCT03370913) study of valoctocogene roxaparvovec (val-rox; Roctavian; BioMarin), the BLA filing for which was recently delayed by the FDA.1 He is also involved in studies on etranacogene dezaparvovec by UniQure and another program by Bayer and recently coauthored a paper exploring novel approaches to treating hemophilia A.2

REFERENCES
1. BioMarin delays hemophilia a therapy valoctocogene roxaparvovec filing as FDA calls for more data. News release. BioMarin. May 31, 2022. https://www.biospace.com/article/fda-needs-more-data-for-biomarin-s-hemophilia-a-therapy/
2. Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol. Published online January 6, 2022. doi:10.1080/14712598.2022.2002842

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.